Metastatic Breast Cancer
From the Journals
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
Conference Coverage
Circulating Tumor DNA Predicts Early Treatment Response in Patients With HER2-Positive Cancers
New study results suggest ctDNA dynamics provide an early window into predicting response to targeted therapies in patients with HER2-altered...
Conference Coverage
Repeat MCED Testing May ID Early-Stage and Unscreened Cancers
Eight of 26 patients with cancer signals detected through MCED had cancer.
Conference Coverage
ImPrint Identifies Patients With Breast Cancer Likely to Respond to Neoadjuvant Immunotherapy
Experts discuss the first randomized clinical study to assess the efficacy of immunotherapy in patients with HR+/HER2- breast cancer.
From the Journals
Less Than 50% of Accelerated Approvals Show Clinical Benefit
Researchers review 46 cancer drugs granted accelerated approvals between 2013 and 2017.
News from the FDA/CDC
FDA Expands Enhertu Indication to HER2-Positive Solid Tumors
The agent had already been approved for several cancer types.
From the Journals
Virtual Reality Brings Relief to Hospitalized Patients With Cancer
Patients were randomized to receive either 10 minutes of immersive VR distraction therapy or 10 minutes of two-dimensional guided imagery...
Feature
Should Opioids Be Used for Chronic Cancer Pain?
Prescribing strategies are partly driven by peer pressure, new research suggests.
Commentary
A Banned Chemical That Is Still Causing Cancer
This carcinogen ‘is still around: in our soil, in our food, and in our blood.’
From the Journals
Active Surveillance for Cancer Doesn’t Increase Malpractice Risk
Researchers identify malpractice trends involving active surveillance related to thyroid, prostate, kidney, and...
Latest News
New Guidance for the Treatment of Metastatic Breast Cancer
The ABC International Consensus Guidelines discuss situations in clinical practice that don’t have strong data suggesting the best path to take....